Trials / Completed
CompletedNCT01598077
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell carcinoma of head and neck, or esophagus, or HER2 overexpressing metastatic breast cancer or gastric cancer
Conditions
- HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- HER2 + Breast Cancer
- HER2 + Gastric Cancer
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LJM716 |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2014-03-01
- Completion
- 2014-03-01
- First posted
- 2012-05-15
- Last updated
- 2020-12-19
Locations
8 sites across 5 countries: United States, Canada, South Korea, Spain, Taiwan
Source: ClinicalTrials.gov record NCT01598077. Inclusion in this directory is not an endorsement.